Skip to Main Content

Paper Details

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
Nat Commun
102
2019
AML, Crenolanib, FLT3, FLT3 mutations, FLT3-independent subclones, FLT3-mutant, FLT3-mutant clones, IDH1, IDH2, NRAS, TET2, acute myeloid leukemia, crenolanib, epigenetic, internal tandem duplications, patient, patients, relapsed/, tyrosine, tyrosine kinase domain, tyrosine kinase domain mutations
Adult, Aged, Aged, 80 and over, Animals, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Cell Line, Tumor, Drug Resistance, Neoplasm, Drug Screening Assays, Antitumor, Epigenesis, Genetic, Exome Sequencing, Female, GTP Phosphohydrolases, HEK293 Cells, Humans, Inhibitory Concentration 50, Isocitrate Dehydrogenase, Leukemia, Myeloid, Acute, Male, Membrane Proteins, Mice, Middle Aged, Mutation, Piperidines, Protein Kinase Inhibitors, Pyridones, Pyrimidinones, Tandem Repeat Sequences, Treatment Outcome, fms-Like Tyrosine Kinase 3
Author NameAffiliation
Haijiao ZhangOregon Health & Science University Knight Cancer Institute
Haijiao ZhangOregon Health & Science University Knight Cancer Institute
Samantha L SavageOregon Health & Science University Knight Cancer Institute
Samantha L SavageOregon Health & Science University Knight Cancer Institute
Anna Reister SchultzOregon Health & Science University Knight Cancer Institute
Anna Reister SchultzOregon Health & Science University Knight Cancer Institute
Daniel BottomlyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute
Libbey WhiteDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute
Erik SegerdellDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute
Beth WilmotDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute
Christopher A EideOregon Health & Science University Knight Cancer Institute
Christopher A EideHoward Hughes Medical Institute
Tamilla NechiporukOregon Health & Science University Knight Cancer Institute
Tamilla NechiporukOregon Health & Science University Knight Cancer Institute
Amy CarlosKnight Cancer Institute, Oregon Health & Science University Knight Cancer Institute
Rachel HensonKnight Cancer Institute, Oregon Health & Science University Knight Cancer Institute
Chenwei LinKnight Cancer Institute, Oregon Health & Science University Knight Cancer Institute
Chenwei LinKnight Cancer Institute, Oregon Health & Science University Knight Cancer Institute
Robert P SearlesKnight Cancer Institute, Oregon Health & Science University Knight Cancer Institute
Hoang HoAROG Pharmaceuticals
Yee Ling LamAROG Pharmaceuticals
Richard S SweatAROG Pharmaceuticals
Courtney FollitAROG Pharmaceuticals
Vinay K JainAROG Pharmaceuticals
Evan F LindOregon Health & Science University Knight Cancer Institute
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Jorge CortesThe University of Texas MD Anderson Cancer Center
Robert H CollinsUniversity of Texas Southwestern Medical Center
Daelynn R BuelowThe Ohio State University College of Pharmacy and Comprehensive Cancer Center
Sharyn D BakerThe Ohio State University College of Pharmacy and Comprehensive Cancer Center
Brian J DrukerOregon Health & Science University Knight Cancer Institute
Brian J DrukerHoward Hughes Medical Institute
Jeffrey W TynerOregon Health & Science University Knight Cancer Institute
Jeffrey W TynerOregon Health & Science University Knight Cancer Institute
  • 1 - 38

Datasets

Release 1.2